A 22-year-old guitarist was admitted to the GHG Medical Center in April 2021 with recurrent epistaxis. After undergoing the necessary examinations, he was diagnosed with myelodysplastic syndrome (MDS). In June 2021, the patient successfully underwent an allogeneic hematopoietic stem cell transplantation. One month and six months after the transplant, however, he developed grade IV intestinal graft rejection. Unable to take in nutrition through the gastrointestinal tract, he was dependent solely on parenteral nutrition, which posed a major challenge for maintaining adequate energy intake, protecting vital organs, and managing multiple complications. After active and comprehensive treatment provided by the GHG medical team, the patient finally overcame the disease. More than two years after the allogeneic transplantation, he completed follow-up care and achieved complete remission of the underlying condition with a good overall recovery. He has now returned to normal work and daily life.
“I was discharged from the transplant unit after 20 days. At that time, I felt very optimistic, but I was also deeply afraid that I would develop severe intestinal rejection after leaving the hospital. My attending physician is the best doctor I have ever met in any hospital. While I was hospitalized, whenever I felt unwell, I called her, and she would come and gently ask, ‘Baby, what’s wrong?’ I stayed in the hospital for such a long time, yet remained in good spirits thanks to her care. She continued answering my questions even after I returned home and wasn’t feeling well. I am grateful to the GHG medical team for saving my life and healing both my physical and emotional wounds.”
Mr. W’s story and his struggle with paroxysmal nocturnal hemoglobinuria (PNH) began nine years ago. For a long time, he experienced persistent fatigue and shortness of breath, initially attributing these symptoms to his workload. However, the symptoms gradually worsened, until one day his urine turned a dark, “soy sauce–like” color—an alarming sign that could not be ignored. Examination at a local hospital confirmed the diagnosis: PNH combined with aplastic anemia (AA), a rare acquired clonal disorder of hematopoietic stem cells characterized by intravascular hemolysis, bone marrow suppression, and a high risk of thrombosis. For many years, he required hormone therapy and periodic blood transfusions, yet his hemoglobin level remained at 50–60 g/L, causing severe weakness and greatly reducing his quality of life.
At the beginning of 2024, his condition deteriorated sharply: hemolytic episodes became more frequent, hemoglobin dropped below 40 g/L, and he experienced increasing abdominal pain and a greater need for transfusions. As a teacher, Mr. W thoroughly researched information about the disease and learned that PNH combined with AA can be cured through allogeneic hematopoietic stem cell transplantation (allo-HSCT). HLA typing revealed that his brother was a fully matched donor. On the recommendation of other patients, he sought treatment at the GoBroad Chunfu Institute.
After a comprehensive evaluation, Director Zeng presented two treatment options: lifelong complement inhibitor therapy to control symptoms, or stem cell transplantation from a fully matched donor to achieve complete cure. After discussing the options with his family, Mr. W chose transplantation. Prior to the procedure, he received eculizumab, which effectively reduced hemolysis and increased his hemoglobin level to 94 g/L, improving his overall condition.
On October 15, 2024, he was admitted to the transplant unit for pre-transplant conditioning, and on October 24 he received peripheral blood stem cells donated by his brother. During the post-transplant period, he developed several complications, including pneumonia, mucosal ulcers, abdominal pain, headaches, and fever—typical issues for immunocompromised patients. Under the close supervision of Zeng Yuanying and her team, his treatment was adjusted promptly, helping him navigate the most critical stages of recovery. Thanks to professional care and strong family support, his blood counts gradually improved, and by November 15 he successfully met the discharge criteria for leaving the transplant unit.
Commenting on the case, Zeng Yuanying noted that despite advances in complement inhibitor therapy, its effectiveness is limited in patients with combined PNH and AA. Even in the era of targeted therapies, allogeneic stem cell transplantation remains the only curative treatment for PNH. She emphasized that persistent anemia accompanied by signs of hemolysis requires mandatory evaluation for PNH, and timely diagnosis and treatment significantly improve outcomes.
Today, Mr. W continues his recovery, with his condition steadily improving as he gradually returns to a full and active life. The banner he presented stands not only as a token of gratitude but also as a testament to the professionalism, dedication, and high standard of medical care at the GoBroad Chunfu Institute of Hematology and Oncology.
After being diagnosed with T-cell lymphoblastic lymphoma at another hospital, Yiyi experienced several central relapses. She received multiple rounds of high-dose methotrexate and repeated intrathecal injections but did not achieve remission. When she was admitted to GHG Medical Centers, Professor Yonghong ZHANG’s team thoroughly reviewed her previous treatments and determined that her symptoms did not align with a central relapse. Further tests revealed that Yiyi had a concurrent cytomegalovirus infection, leading to a diagnosis of cytomegalovirus encephalitis.
Following antiviral treatment, the abnormal cells in her central nervous system disappeared, and Yiyi’s condition improved quickly. Her subsequent treatments went well, and she achieved complete remission, which has persisted. Yiyi, who enjoys singing and dancing, is now able to perform on stage again.
Lele, a boy, was diagnosed with classical Hodgkin lymphoma in October 2022. At the recommendation of the wardmates, his parents took him to GHG medical center. After a comprehensive examination and evaluation of Lele, the GHG medial team considered not only the current response and cure but also the long-term non-serious toxic and side effects for the therapeutic regimen and finally developed a standardized treatment regimen with precise stratification.
After 6 courses of chemotherapy, Lele has achieved a complete remission. At the time of discharge, he said happily, “I can finally say goodbye to the hospital! I’m sure I’ll have handsome hair! I will run on the playground on sunny days like my classmates!”
Seven-year-old Tiantian, who was only one year old in 2017, underwent a hematology test at the local children’s hospital due to persistent fever. The results showed hemoglobin at 50 g/L, and he was diagnosed with major β-thalassemia with a double HBB mutation. When Tiantian was diagnosed, he already showed very obvious symptoms of anemia and required a red blood cell transfusion. As Tiantian grew older, the strain on his circulatory system increased as well. The number of blood transfusions rose from 2 to 3 units each time, almost every other month, to keep his hemoglobin level around 90 g/L.
In 2022, Tiantian and his parents came to the GHG Medical Center. Thanks to the efforts of the medical team, Tiantian underwent a TDH transplant. Today, Tiantian no longer needs medication and has returned to a happy childhood.
“We knew that the success rate of thalassemia transplantation performed by the GHG medical team is 97%, and compared with the possible risks, we chose to trust the team’s many years of experience in thalassemia transplantation. Every month he had to be admitted to the hospital for blood transfusions and iron chelation, and he stayed at least two days each time. Because the injections were so frequent and his blood vessels were narrowing, it often took 2–3 attempts before an injection succeeded. As his parents, it was heartbreaking. We are grateful to the doctors and nurses. It is thanks to them that Tiantian can now have a normal and happy childhood like other children.”
Linlin, a 13-year-old girl, was diagnosed with acute B-lymphoblastic leukemia in 2018. However, she had no response to multiple courses of chemotherapy. She received the first hematopoietic stem cell transplant in her hometown in October 2019. Unfortunately, her leukemia relapsed in October 2020.
Linlin came to GHG medical center with her parents for further treatment in 2021. She was recommended to first receive CAR-T treatment, followed by hematopoietic stem cell transplant after careful evaluation by GHG medical team. Accompanied by the GHG team, she successfully received CAR-T therapy and the second hematopoietic stem cell transplant. She went through difficulties including nausea, vomiting, fever, and rejection and was discharged from the hospital. More than two years have passed
since the second transplant, and there have been no other serious post-transplant complications. Linlin said happily, “The sky in Beijing is so blue.” when she walked out from GHG medical center because she had a good re-examination recently.
Anan, a girl, was diagnosed with acute lymphoblastic leukemia in 2014 when she was 4 years old, and her condition was stable after multiple courses of chemotherapy for more than 3 years. The patient achieved a response after CAR-T therapy in 2020. She came to GHG medical center for further diagnosis and treatment due to a second relapse of leukemia in 2021.
After reviewing Anan’s past medical history and various examination reports, the team proposed chemotherapy first and completed lumbar puncture intrathecal injection targeting a stable condition. After her condition was initially stable, the team proposed a sequential CAR-T therapy program. The doctor’s rich treatment experience and logically clear treatment thoughts gave Anan’s family confidence.
She achieved a very good response after CAR-T therapy. Although the effect of CART therapy was currently very good, the team recommended seizing the opportunity to bridge allogeneic hematopoietic stem cell transplant after CAR-T therapy according to the latest clinical research and comprehensive judgment of her condition and explained the new program of TDH in detail. Compared with other transplant programs, TDH had lower requirements for donor matching, faster recovery and fewer complications, especially the success rate of transplant, which gave her family great confidence. After the transplant, both Anan’s indicators and mental status were very good. After more than 9 years of fighting with leukemia by chemotherapy, CAR-T, and bridging to allogeneic hematopoietic stem cell transplant after CAR-T therapy, Anan also began to look forward to returning to school after recovery.
In 2017, six-year-old Tian Tian was diagnosed with Burkitt lymphoma. Despite undergoing several rounds of high-dose chemotherapy as the first line of treatment, he did not reach complete remission. He then received second-line chemotherapy, but the tumor continued to grow.
To further address his condition, Tian Tian was treated at GHG Medical Centers. After a thorough evaluation, Professor Yonghong ZHANG created a personalized treatment plan for him. Due to the tumor’s persistent progression, Tian Tian had three biopsies and underwent sequential CAR-T cell therapy targeting CD19, CD22, and CD20. Ultimately, he achieved complete remission, which he has maintained to this day. Now as middle school student, he leads a normal life, studying and enjoying time with friends.
Tian Tian is recognized as the first patient i with refractory/relapsed Burkitt lymphoma (R/R BL) to attain complete remission through the sequential infusion of CD19/CD20/CD22 CAR-T cells. This groundbreaking therapy offers a new treatment option for refractory relapsed Burkitt lymphoma.
